The psychedelics and cannabis sectors share a lot of similarities – is profit potential one of them? Here’s what to know…
Over the past year, we’ve watched psychedelics transform from a fringe sector of holistic medicine to a legitimate pharmaceutical industry backed by venture capital heavyweights like Peter Thiel.
Thiel, the legendary billionaire entrepreneur, helped launch German psychedelics startup Atai Life Sciences (Nasdaq: ATAI) onto the world stage earlier this year – making it the third psychedelics company to IPO on a major exchange.
And it won’t be the last.
These companies are tapping into ancient psychedelic compounds whose therapeutic applications are only now being clinically applied to treat debilitating conditions like depression, anxiety, PTSD, and addiction.
And much like with cannabis, as the research surrounding these drugs rapidly develops, we’re realizing that their healing capabilities are groundbreaking…
Groundbreaking enough to potentially create a $10.7 billion psychedelics market by 2028.
We’ve seen the former pure-play cannabis company Vireo Health International Inc. enter the psychedelics space and emerge as Goodness Growth Holdings Inc. (OTC: GDNSF).
But we’re still in the very early phases of this opportunity, and there’s a lot to learn.
To find out whether the psychedelics market has as much profit potential as cannabis, I connected with Advisory Board Member Charles Delvalle for another episode of Underrated or Overrated?
And – spoiler alert – we had some disagreements.
To your investing success,
Executive Director, National Institute for Cannabis Investors
August 24 2021